|
1
|
John AM and Schwartz RA: Glucagonoma
syndrome: A review and update on treatment. J Eur Acad Dermatol
Venereol. 30:2016–2022. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mountjoy L and Kollmorgen D:
Glucagonoma-associated rash. N Engl J Med. 376(e18)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cunha-Silva M, da Costa JG, Faria GA,
Massuda JY, Cintra ML, da Costa LB, Assad VM, de Ataíde EC, Mazo DF
and Sevá-Pereira T: Diarrhea: A missed D in the 4D glucagonoma
syndrome. Autops Case Rep. 9(e2019129)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bosch-Amate X, Riera-Monroig J and Iranzo
Fernández P: Glucagonoma-related necrolytic migratory erythema. Med
Clin (Barc): Sep 9, 2019 (Epub ahead of print). doi:
10.1016/j.medcli.2019.06.027.
|
|
5
|
Maurelli M, Gisondi P and Girolomoni G:
Visual Vignette. Endocr Pract. 26(253)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Guilbaud T, Berbis P and Birnbaum DJ:
Glucagonoma with paraneoplasic dermatitis: Diagnosis and
management. J Gastrointest Surg. 24:701–703. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wei J, Song X, Liu X, Ji Z, Ranasinha N,
Wu J and Miao Y: Glucagonoma and glucagonoma syndrome: One center's
experience of six cases. J Pancreat Cancer. 4:11–16.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
V'lckova-Laskoska M, Balabanova-Stefanova
M, Arsovska-Bezhoska I, Caca-Biljanovska N and Laskoski D:
Necrolytic migratory erythema: Complete healing after surgical
removal of pancreatic carcinoma. Acta Dermatovenerol Croat.
26:329–332. 2018.PubMed/NCBI
|
|
9
|
Al-Faouri A, Ajarma K, Alghazawi S,
Al-Rawabdeh S and Zayadeen A: Glucagonoma and glucagonoma syndrome:
A case report with review of recent advances in management. Case
Rep Surg. 2016(1484089)2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wewer Albrechtsen NJ, Kuhre RE, Pedersen
J, Knop FK and Holst JJ: The biology of glucagon and the
consequences of hyperglucagonemia. Biomarkers Med. 10:1141–1151.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Adeva-Andany MM, Funcasta-Calderón R,
Fernández-Fernández C, Castro-Quintela E and Carneiro-Freire N:
Metabolic effects of glucagon in humans. J Clin Transl Endocrinol.
15:45–53. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Müller TD, Finan B, Clemmensen C, DiMarchi
RD and Tschöp MH: The new biology and pharmacology of glucagon.
Physiol Rev. 97:721–766. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dumitrascu MC, Stanescu AMA, Bejan C,
Sandru F, Toader DO, Radavoi DG, Cotirlet A, Pusta CTJ and Diaconu
CC: Obesity and its implications on stress urinary incontinence.
Rev Chim Bucharerst. 70:3660–3662. 2019.
|
|
14
|
Silaghi AC, Poantă L, Valea A, Pais R and
Silaghi H: Is epicardial adipose tissue, assessed by
echocardiography, a reliable method for visceral adipose tissue
prediction? Med Ultrason. 13:15–20. 2011.PubMed/NCBI
|
|
15
|
Ahrén B: Glucagon - Early breakthroughs
and recent discoveries. Peptides. 67:74–81. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Stensen S, Gasbjerg LS, Helsted MM,
Hartmann B, Christensen MB and Knop FK: GIP and the gut-bone axis -
Physiological, pathophysiological and potential therapeutic
implications. Peptides. 170197(2019)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Holst JJ: Incretin therapy for diabetes
mellitus type 2. Curr Opin Endocrinol Diabetes Obes. 27:2–10.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Müller TD, Finan B, Bloom SR, D'Alessio D,
Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF,
et al: Glucagon-like peptide 1 (GLP-1). Mol Metab. 30:72–130.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Albulescu DM, Carsote M, Ionovici N,
Ghemigian A, Popescu M, Tuculina MJ, Dascalu IT, Preda SA, Tirca T,
Petrescu MS, et al: 5-Hydroxytriptamine and skeleton influence
Clinical study. Rev Chim Buchar. 69:2438–2442. 2018.
|
|
20
|
Öberg K: Management of functional
neuroendocrine tumors of the pancreas. Gland Surg. 7:20–27.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Poiană C, Neamţu MC, Avramescu ET, Carşote
M, Trifănescu R, Terzea D, Neamţu OM, Ferechide D and Dănciulescu
Miulescu R: The poor prognosis factors in G2 neuroendocrine tumor.
Rom J Morphol Embryol. 54 (Suppl 3):717–720. 2013.PubMed/NCBI
|
|
22
|
Carşote M, Păun S, Neamţu MC, Avramescu
ET, Iosif C, Terzea D, Constantinoiu S, Dănciulescu Miulescu R,
Neamţu OM and Poiană C: The immunohistochemistry aspects in two
cases of neurofibromatosis-associated abdominal tumors. Rom J
Morphol Embryol. 53:401–405. 2012.PubMed/NCBI
|
|
23
|
Lv WF, Han JK, Liu X, Wang SC, Pan BO and
Xu AO: Imaging features of glucagonoma syndrome: A case report and
review of the literature. Oncol Lett. 9:1579–1582. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kawsar HI, Habib A and Saeed A and Saeed
A: Unremitting chronic skin lesions: A case of delayed diagnosis of
glucagonoma. J Community Hosp Intern Med Perspect. 9:425–429.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cao X, Wang X, Lu Y, Zhao B, Shi J, Guan Q
and Zhang X: Spleen-preserving distal pancreatectomy and
lymphadenectomy for glucagonoma syndrome: A case report. Medicine
(Baltimore). 98(e17037)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang ZX, Wang F and Zhao JG: Glucagonoma
syndrome with severe erythematous rash: A rare case report.
Medicine (Baltimore). 98(e17158)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Song X, Zheng S, Yang G, Xiong G, Cao Z,
Feng M, Zhang T and Zhao Y: Glucagonoma and the glucagonoma
syndrome. Oncol Lett. 15:2749–2755. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Anderson CW and Bennett JJ: Clinical
presentation and diagnosis of pancreatic neuroendocrine tumors.
Surg Oncol Clin N Am. 25:363–374. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Toberer F, Hartschuh W and Wiedemeyer K:
Glucagonoma-associated necrolytic migratory erythema: The broad
spectrum of the clinical and histopathological findings and clues
to the diagnosis. Am J Dermatopathol. 41:e29–e32. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tolliver S, Graham J and Kaffenberger BH:
A review of cutaneous manifestations within glucagonoma syndrome:
Necrolytic migratory erythema. Int J Dermatol. 57:642–645.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ochi N, Kawahara T, Yamane H and Takigawa
N: Erythema as a visual surrogate marker of glucagonoma. Intern
Med. 57:2283–2284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
He S, Zeng W, Geng S and Jia J:
Glucagonoma syndrome with atypical necrolytic migratory erythema.
Indian J Dermatol Venereol Leprol: Aug 1, 2019 (Epub ahead of
print). doi: 10.4103/ijdvl.IJDVL_588_18.
|
|
33
|
Martínez Manzano Á, Balsalobre Salmerón
MD, García López MA, Soto García S and Vázquez Rojas JL:
Psoriasiform lesions: Uncommon presentation of glucagonoma.
Gastroenterol Hepatol. 41:500–502. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tremblay C and Marcil I: Necrolytic
migratory erythema: A forgotten paraneoplastic condition. J Cutan
Med Surg. 21:559–561. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jiménez-Gallo D, Ossorio-García L, de la
Varga-Martínez R, Arjona-Aguilera C and Linares-Barrios M:
Necrolytic migratory erythema associated with glucagonoma treated
successfully with cyclosporine. Dermatol Ther (Heidelb).
30(e12498)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Parbhu SK and Adler DG: Pancreatic
neuroendocrine tumors: contemporary diagnosis and management. Hosp
Pract (1995). 44:109–119. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Rosenbaum JN and Lloyd RV: Pancreatic
neuroendocrine neoplasms. Surg Pathol Clin. 7:559–575.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Granberg D: Biochemical testing in
patients with neuroendocrine tumors. Front Horm Res. 44:24–39.
2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Rodríguez G, Vargas E, Abaúnza C and
Cáceres S: Necrolytic migratory erythema and pancreatic
glucagonoma. Biomedica. 36:176–181. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhang P, Li YL, Qiu XD, Luo J, Shi YF, Sun
YL, Su F, Qi ZR and Tan HY: Clinicopathological characteristics and
risk factors for recurrence of well-differentiated pancreatic
neuroendocrine tumors after radical surgery: A case-control study.
World J Surg Oncol. 17(66)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Barabas M, Huang-Doran I, Pitfield D,
Philips H, Goonewardene M, Casey RT and Challis BG:
Glucagonoma-associated dilated cardiomyopathy refractory to
somatostatin analogue therapy. Endocrinol Diabetes Metab Case Rep:
Mar 5, 2019 (Epub ahead of print). doi: 10.1530/EDM-18-0157.
|
|
42
|
Saavedra C, Lamarca A and Hubner RA:
Resolution of necrolytic migratory erythema with somatostatin
analogue in a patient diagnosed with pancreatic glucagonoma. BMJ
Case Rep. 12(e229115)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Halperin DM, Kulke MH and Yao JC: A tale
of two tumors: Treating pancreatic and extrapancreatic
neuroendocrine tumors. Annu Rev Med. 66:1–16. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dimitriadis GK, Weickert MO, Randeva HS,
Kaltsas G and Grossman A: Medical management of secretory syndromes
related to gastroenteropancreatic neuroendocrine tumours. Endocr
Relat Cancer. 23:R423–R436. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jin XF, Spampatti MP, Spitzweg C and
Auernhammer CJ: Supportive therapy in gastroenteropancreatic
neuroendocrine tumors: Often forgotten but important. Rev Endocr
Metab Disord. 19:145–158. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Gut P, Waligórska-Stachura J, Czarnywojtek
A, Sawicka-Gutaj N, Bączyk M, Ziemnicka K, Fischbach J, Woliński K,
Kaznowski J, Wrotkowska E, et al: Management of the hormonal
syndrome of neuroendocrine tumors. Arch Med Sci. 13:515–524.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wick MR and Patterson JW: Cutaneous
paraneoplastic syndromes. Semin Diagn Pathol. 36:211–228.
2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Eldor R, Glaser B, Fraenkel M, Doviner V,
Salmon A and Gross DJ: Glucagonoma and the glucagonoma
syndrome-cumulative experience with an elusive endocrine tumour.
Clin Endocrinol (Oxf). 74:593–598. 2011.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Guilmette J and Nosé V: Paraneoplastic
syndromes and other systemic disorders associated with
neuroendocrine neoplasms. Semin Diagn Pathol. 36:229–239.
2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ahmad Z, Shastry S, Vuitch F and Garg A:
Cirrhosis-induced pseudoglucagonoma syndrome in a patient with type
2 diabetes: An autopsy study. Clin Endocrinol (Oxf). 74:658–660.
2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Liu JW, Qian YT and Ma DL: Necrolytic
migratory erythema. JAMA Dermatol: Jul 24, 2019 (Epub ahead of
print). doi: 10.1001/jamadermatol.2019.1658.
|
|
52
|
Virani S, Prajapati V, Devani A, Mahmood
MN and Elliott JF: Octreotide-responsive necrolytic migratory
erythema in a patient with pseudoglucagonoma syndrome. J Am Acad
Dermatol. 68:e44–e46. 2013.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zhang M, Tang X, Zhou H, Liao Q and Han J:
Case of autoimmune progesterone dermatitis presenting as necrotic
migratory erythema successfully controlled by danazol. J Dermatol.
47:178–180. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Taskin OC and Adsay V: Lipase
hypersecretion syndrome: A distinct form of paraneoplastic syndrome
specific to pancreatic acinar carcinomas. Semin Diagn Pathol.
36:240–245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Cornacchia C, Rutigliani M, Serventi A,
Ciferri E, Angelini G and Filauro M: Pancreatic ductal
adenocarcinoma derived from an intraductal papillary neoplasm with
synchronous incidental glucagonoma: A case report and literature
review. Pancreas. 48:e24–e26. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Gheorghisan-Galateanu AA, Carsote M and
Valea A: Incidentaloma: From general practice to specific endocrine
frame. J Pak Med Assoc. 67:917–922. 2017.PubMed/NCBI
|
|
57
|
Solomon I, Voiculescu VM, Caruntu C, Lupu
M, Popa A, Ilie MA, Albulescu R, Caruntu A, Tanase C, Constantin C,
et al: Neuroendocrine factors and head and neck squamous cell
carcinoma: An affair to remember. Dis Markers.
2018(9787831)2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Ion A, Popa IM, Papagheorghe LML,
Lisievici C, Lupu M, Voiculescu V, Caruntu C and Boda D: Proteomic
approaches to biomarker discovery in cutaneous T-cell lymphoma. Dis
Markers. 2016(9602472)2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013.
|
|
60
|
Ilie MA, Caruntu C, Lupu M, Lixandru D,
Tampa M, Georgescu SR, Bastian A, Constantin C, Neagu M, Zurac SA,
et al: Current and future applications of confocal laser scanning
microscopy imaging in skin oncology. Oncol Lett. 17:4102–4111.
2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Căruntu C, Boda D, Guţu DE and Căruntu A:
In vivo reflectance confocal microscopy of basal cell carcinoma
with cystic degeneration. Rom J Morphol Embryol. 55:1437–1441.
2014.PubMed/NCBI
|
|
62
|
Georgiou GK, Gizas I, Katopodis KP and
Katsios CS: Non-secreting benign glucagonoma diagnosed incidentally
in a patient with refractory thrombocytopenic thrombotic purpura:
Report of a case. Surg Today. 45:1317–1320. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Mai VQ, Jones RC, Dickert JM, Clyde PW and
Shakir KM: Plasma glucagon levels suppressed by a glucose load in a
man with incidental pancreatic glucagonoma. Endocr Pract.
13:780–784. 2007.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Wewer Albrechtsen NJ, Challis BG, Damjanov
I and Holst JJ: Do glucagonomas always produce glucagon? Bosn J
Basic Med Sci. 16:1–7. 2016.PubMed/NCBI View Article : Google Scholar
|
